匯智協(xié)和公司 創(chuàng)始人，首席執(zhí)行官
前強(qiáng)生(J&J)全球創(chuàng)新合作戰(zhàn)略聯(lián)盟 全球總監(jiān)
李秀艷博士專長(zhǎng)以多方合作尤其是跨境合作的方式開發(fā)上市高價(jià)值的醫(yī)藥健康產(chǎn)品。她領(lǐng)導(dǎo)的匯智協(xié)和專注幫助中國(guó)企業(yè)國(guó)際化，轉(zhuǎn)讓其產(chǎn)品的國(guó)際權(quán)益及建立適宜的境外銷售渠道，并幫助中國(guó)企業(yè)境內(nèi)境外尋找合適的產(chǎn)品技術(shù)或合作伙伴。李秀艷博士獲美國(guó)康州大學(xué)藥學(xué)博士，之前獲北京大學(xué)化學(xué)系學(xué)士和碩士學(xué)位。曾任職Honeywell, AMRI, Covidien, J&J 強(qiáng)生，方達(dá)，藥明康德等多家國(guó)內(nèi)國(guó)外知名企業(yè)。 職涯前12年迅速從一線研發(fā)科學(xué)家成長(zhǎng)為跨界產(chǎn)品創(chuàng)新的領(lǐng)軍人，直接領(lǐng)導(dǎo)并參與了多個(gè)新藥，仿制藥，大健康產(chǎn)品，輔料，高純?cè)噭┘安牧系拈_發(fā)，包括生產(chǎn)工藝開發(fā)，分析方法開發(fā)，中試生產(chǎn)，及大規(guī)模生產(chǎn)的技術(shù)轉(zhuǎn)移。中期6年在國(guó)際知名的健康產(chǎn)品開發(fā)公司強(qiáng)生負(fù)責(zé)產(chǎn)品的全球外包生產(chǎn)和新劑型產(chǎn)品的創(chuàng)新合作，外包產(chǎn)品價(jià)值2.5億美元，合作開發(fā)產(chǎn)品管線價(jià)值10億美元。得益于與超過200多家的CRDMO， DDS， Biotech and pharma企業(yè)的交流訪問及合作，積累了豐富的技術(shù)評(píng)估，外包或供應(yīng)商盡職調(diào)查，合同洽談的經(jīng)驗(yàn)。近5年供職中美著名外包服務(wù)企業(yè)，領(lǐng)導(dǎo)在中國(guó)的產(chǎn)品開發(fā)申報(bào)的服務(wù)，向中國(guó)引進(jìn)先進(jìn)的醫(yī)療健康產(chǎn)品和技術(shù)，幫助中國(guó)企業(yè)國(guó)際化，更深刻地理解了中國(guó)市場(chǎng)和企業(yè)的需求。2015年底合伙創(chuàng)立匯智協(xié)和。她還兼任世中聯(lián)經(jīng)皮給藥專業(yè)委員會(huì)會(huì)副主席，兒童產(chǎn)品聯(lián)盟籌委會(huì)委員。
Dr. Cheryl Li, currently CEO and CO-founder of PharmaSynergy, was honored to have served in several reputable CRDMO, global pharmaceutical and consumer product companies including Wuxi Apptec, J&J, Covidien, AMRI. She has over 20 years in-depth industry experience with increasing responsibilities in a wide range of professional areas including product development (API and FGs), R&D outsourcing, external manufacturing, product in-licensing and strategic partnership, product due diligence, and business contract negotiation. She had assessed more than 200 CRO/CMO and DDS firms as well as API and Packaging companies globally and is familiar with how the businesses are conducted in different parts of the world. She received her Ph.D. degree in Pharmaceutical Sciences from UCONN, MS and BS degrees in Chemistry from Peking University. She has been widely involved in various professional organizations, currently serving as VP of China Transdermal Society and the Organizing Committee member for Children’s Products Association.
隆安律師事務(wù)所 合伙人/執(zhí)業(yè)律師、專利代理人
隆安律師事務(wù)所合伙人/執(zhí)業(yè)律師、專利代理人，魯律師先后就讀于華東政法大學(xué)法律學(xué)院、上海交通大學(xué)藥學(xué)院。擁有法學(xué)、藥學(xué)等領(lǐng)域的復(fù)合背景，擅長(zhǎng)醫(yī)藥領(lǐng)域創(chuàng)新成果知識(shí)產(chǎn)權(quán)保護(hù)、醫(yī)藥創(chuàng)新技術(shù)成果轉(zhuǎn)化、醫(yī)藥項(xiàng)目投融資及CFDA/FDA政策咨詢等。曾主持某505B(2)新藥項(xiàng)目的投融資及中美雙報(bào)評(píng)估；主辦某藥品配方商業(yè)秘密侵權(quán)案（涉案標(biāo)的約1億）、某創(chuàng)新生物藥企基因測(cè)序?qū)＠夹g(shù)B輪融資項(xiàng)目（融資規(guī)模1.2億）、上海交大某創(chuàng)新制劑專利復(fù)審、某上市公司知識(shí)產(chǎn)權(quán)戰(zhàn)略規(guī)劃等；并為多家醫(yī)藥上市公司進(jìn)行國(guó)際專利布局，為國(guó)內(nèi)外多家高科技企業(yè)提供知識(shí)產(chǎn)權(quán)保護(hù)及投融資服務(wù)，具有多家新藥高科技初創(chuàng)公司成果轉(zhuǎn)化及融資經(jīng)驗(yàn)。
隆安成立于1992年，是中國(guó)最早的合伙制律師事務(wù)所之一, 現(xiàn)有員工人數(shù)約1200人。在過去的二十五年里，隆安為包括世界500強(qiáng)在內(nèi)的眾多大中型企業(yè)提供了并購、金融、外商直接投資、知識(shí)產(chǎn)權(quán)、大型項(xiàng)目等領(lǐng)域的法律服務(wù)。隆安多次被全國(guó)律師管理機(jī)構(gòu)評(píng)為中國(guó)最為優(yōu)秀的律師事務(wù)所之一。憑借近年來的整體實(shí)力，隆安成功入圍《亞洲法律雜志》年度多項(xiàng)法律大獎(jiǎng)，入選中國(guó)十佳成長(zhǎng)律所，并以前十的成績(jī)榮登亞洲最大50家律所及中國(guó)律所30強(qiáng)榜單。隆安亦在英國(guó)《律師》雜志亞太地區(qū)百強(qiáng)律所榜單及中國(guó)精英律所30強(qiáng)榜單中位居前列。
Mr. Lu Liyan is the partner, lawyer and patent lawyer of Long An Law Firm. Lawyer Lu studied law at East China University of Political Science and Law and studied Pharmaceutical Engineering at Shanghai Jiao Tong University, thus possessing a complex background in law and pharmacy. Lawyer Lu is good at protection of intellectual property involving innovative achievements in the field of medicine, transformation of medical innovative technology achievements, investment and financing of pharmaceutical projects and consultation of CFDA / FDA policy. Lawyer Lu has presided over the investment & financing of a 505B (2) new drug project as well as the evaluation conference of the US-Chinese Application regarding the new drug; has dealt with an infringement of commercial secret regarding a drug formulation; has undertook a B round of financing regarding an innovative biopharmaceutical company's gene sequencing patent; has acted for the reexamination of an innovative formulations patent of Shanghai Jiao Tong University; has designed the intellectual property strategic planning of a listed company; has designed the international patent portfolio for many listed pharmaceutical companies; has been providing services involving the protection of intellectual property and investment & financing for many high-tech enterprises at home and abroad; and experienced in financing and transforming the achievements of many newly established high-tech companies.